☆ 4.7 Meeting Abstract

Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI ± bevacizumab (BV) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)

JOURNAL OF CLINICAL ONCOLOGY (2011)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 29, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/jco.2011.29.15_suppl.3581

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial

Marla Lipsyc-Sharf, Fang-Shu Ou, Matthew B. Yurgelun, Douglas A. Rubinson, Deborah Schrag, Shaker R. Dakhil, Philip J. Stella, Douglas J. Weckstein, Donald B. Wender, Meredith Faggen, Tyler J. Zemla, Erica N. Heying, Samantha R. Schuetz, Stephanie Noble, Jeffrey A. Meyerhardt, Tanios Bekaii-Saab, Charles S. Fuchs, Kimmie Ng

Summary: The study investigated the efficacy of combining bevacizumab with irinotecan and cetuximab in patients with irinotecan-refractory metastatic colorectal cancer. Although there was no significant difference in progression-free survival between the two treatment groups, there was a statistically significant improvement in overall survival favoring the group that received bevacizumab in addition to irinotecan and cetuximab. Further investigation on this combination therapy is warranted.

ONCOLOGIST (2022)

Add to Collection

Article Oncology

Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study

Hiroya Taniguchi, Kentaro Yamazaki, Toshiki Masuishi, Takeshi Kawakami, Yusuke Onozawa, Kazunori Honda, Shigenori Kadowaki, Yukiya Narita, Takahiro Tsushima, Satoshi Hamauchi, Akiko Todaka, Tomoya Yokota, Masashi Ando, Keita Mori, Hiromichi Shirasu, Hirofumi Yasui, Kei Muro

Summary: In this phase Ib study, trifluridine/tipiracil, irinotecan, and bevacizumab were tested in patients with metastatic colorectal cancer. The treatment showed moderate antitumor activity but had a high risk of severe myelotoxicity.

ONCOLOGIST (2023)

Add to Collection

Article Oncology

Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial

Zhan Wang, Bao-Dong Qin, Chen-Yang Ye, Miao-Miao Wang, Ling-Yan Yuan, Wei-Ping Dai, Li Sun, Ke Liu, Wen-Xing Qin, Xiao-Dong Jiao, Xing-Nan Li, Yuan-Sheng Zang

Summary: This study evaluated the safety and efficacy of a new protocol using vemurafenib and cetuximab combined with FOLFIRI in patients with BRAF V600E-mutated colorectal cancer. The results showed promising antitumour activity and tolerable toxicity with this combination therapy.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Clinical Benefit of Bevacizumab and Irinotecan (BEV plus IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors

Ji Hyun Park, Hyun Seok Lee, Jin Woo Choi, So Dug Lim, Hyeon Kang Koh, Kyung Rae Cho, Joon Cho, Young-Cho Koh, So Young Yoon

Summary: The study found that salvage treatment with BEV+IRI in r/rGBM conferred comparable clinical benefit, with ECOG PS >= 3, TP53 loss, and lack of prompt clinical improvement after the treatment significantly associated with an unfavorable overall survival. The efficacy of BEV+IRI and its potential biomarker in r/rGBM patients warrant further investigation.

ANTICANCER RESEARCH (2022)

Add to Collection

Article Oncology

Efficacy and quality of life for FOLFOX/bevacizumab plus /- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial

Hans-Joachim Schmoll, Julia Mann, Fabian Meinert, Benjamin Garlipp, Kersten Borchert, Arndt Vogel, Eray Goekkurt, Ulrich Kaiser, Heinz-Gert Hoeffkes, Joern Ruessel, Stephan Kanzler, Thomas Edelmann, Helmut Forstbauer, Thomas Goehler, Carla Hannig, Bert Hildebrandt, Carsten Roll, Carsten Bokemeyer, Joerg Steighardt, Franziska Cygon, Stefan Ibach, Alexander Stein, Joseph Tintelnot

Summary: The study confirms the effectiveness and tolerability of FOLFOXIRI plus bevacizumab as a first-line treatment for mCRC, but challenges remain in its clinical implementation.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?

Angeline Ginzac, Emilie Thivat, Caroline Petorin, Damien Richard, Pauline Herviou, Ioana Molnar, Herve Devaud, Isabelle Creveaux, Florent Ferrer, Nicolas Authier, Marine Jary, Denis Pezet, Xavier Durando

Summary: The study aimed to assess the safety and efficacy of irinotecan dosage adjusted according to UGT1A1 polymorphism in mCRC patients. The results showed that mCRC patients can tolerate a higher dose of irinotecan based on their UGT1A1 genotype without increased toxicities.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2023)

Add to Collection

Article Oncology

Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials

Stefanie Noepel-Duennebacke, Hendrik Juette, Karsten Schulmann, Ulrich Graeven, Rainer Porschen, Jan Stoehlmacher, Susanna Hegewisch-Becker, Arne Raulf, Dirk Arnold, Anke Reinacher-Schick, Aandrea Tannapfel

Summary: High microsatellite instability (MSI-H) tumors were more frequent in right-sided tumors and correlated with mutant BRAF. PD-L1 expression was not correlated with MSI-H status, but in MSI-H tumors the percentage of PD-L1 positive tumors was higher than in MSS tumors.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer

Toshiki Masuishi, Soshi Nagaoka, Long Jin, Kenichi Yoshizawa

Summary: This study assessed the safety of ramucirumab plus FOLFIRI in patients with metastatic colorectal cancer, finding that the safety profile was similar regardless of patient age and initial irinotecan dose.

DRUGS-REAL WORLD OUTCOMES (2023)

Add to Collection

Review Pharmacology & Pharmacy

Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review

Marta Miarons, Pau Riera, Sara Garcia-Gil, Fernando Gutierrez-Nicolas

Summary: This systematic review analyzes the efficacy and safety of using higher doses of irinotecan in metastatic colorectal cancer patients with UGT1A1*1/*1 or *1/*28 genotypes who are treated with the FOLFIRI regimen. The results suggest that increasing irinotecan dose can improve the objective response rate and progression-free survival. Safety studies indicate that doses higher than 180 mg/m2 are well-tolerated by most UGT1A1*1/*1 and *1/*28 patients.

FARMACIA HOSPITALARIA (2022)

Add to Collection

Article Pharmacology & Pharmacy

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction

Naoko Takebe, Jan H. Beumer, Shivaani Kummar, Brian F. Kiesel, Afshin Dowlati, Geraldine O'Sullivan Coyne, Richard Piekarz, Lawrence Rubinstein, Laura K. Fogli, Ulka Vaishampayan, Sanjay Goel, Cindy L. O'Bryant, Bassel F. El-Rayes, Vincent Chung, Heinz-Josef Lenz, Richard Kim, Chandra P. Belani, Joseph M. Tuscano, William Schelman, Nancy Moore, James H. Doroshow, Alice P. Chen

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)

Add to Collection

Article Biology

Caspase-mediated cleavage of IRE1 controls apoptotic cell commitment during endoplasmic reticulum stress

Anna Shemorry, Jonathan M. Harnoss, Ofer Guttman, Scot A. Marsters, Liszlo G. Komuves, David A. Lawrence, Avi Ashkenazi

ELIFE (2019)

Add to Collection

Article Biology

Misfolded proteins bind and activate death receptor 5 to trigger apoptosis during unresolved endoplasmic reticulum stress

Mable Lam, Scot A. Marsters, Avi Ashkenazi, Peter Walter

ELIFE (2020)

Add to Collection

Article Oncology

Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center

Catherine Michelle Laird, Ashley E. Glode, Kerry Schwarz, Elaine T. Lam, Cindy L. O'Bryant

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2020)

Add to Collection

Article Oncology

IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment

Jonathan M. Harnoss, Adrien Le Thomas, Mike Reichelt, Ofer Guttman, Thomas D. Wu, Scot A. Marsters, Anna Shemorry, David A. Lawrence, David Kan, Ehud Segal, Mark Merchant, Klara Totpal, Lisa M. Crocker, Kathryn Mesh, Monika Dohse, Margaret Solon, Zora Modrusan, Joachim Rudolph, Hartmut Koeppen, Peter Walter, Avi Ashkenazi

CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors

S. Lindsey Davis, Anastasia A. Ionkina, Stacey M. Bagby, James D. Orth, Brian Gittleman, Joshua M. Marcus, Elaine T. Lam, Bradley R. Corr, Cindy L. O'Bryant, Ashley E. Glode, Aik-Choon Tan, Jihye Kim, John J. Tentler, Anna Capasso, Kyrie L. Lopez, Daniel L. Gustafson, Wells A. Messersmith, Stephen Leong, S. Gail Eckhardt, Todd M. Pitts, Jennifer R. Diamond

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Mehmet Akce, Anthony El-Khoueiry, Sarina A. Piha-Paul, Emeline Bacque, Peng Pan, Zhi-Yi Zhang, Reginald Ewesuedo, Divya Gupta, Yongqiang Tang, Ashley Milton, Stefan Zajic, Patricia L. Judson, Cindy L. O'Bryant

Summary: This study aimed to characterize the pharmacokinetics and safety of niraparib in patients with normal hepatic function (NHF) versus moderate hepatic impairment (MHI). The results showed that MHI patients had increased plasma exposure to niraparib compared to NHF patients, but this did not affect tolerability. Adjusting the starting dose of niraparib from 300 mg to 200 mg QD in MHI patients is recommended based on these findings. Safety profiles were consistent across both patient groups.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)

Add to Collection

Article Biology

Neuronal regulated ire-1-dependent mRNA decay controls germline differentiation in Caenorhabditis elegans

Mor Levi-Ferber, Rewayd Shalash, Adrien Le-Thomas, Yehuda Salzberg, Maor Shurgi, Jennifer Ic Benichou, Avi Ashkenazi, Sivan Henis-Korenblit

Summary: The study reveals how ER stress enhances ectopic germline differentiation through regulating a specific neuronal circuit in Caenorhabditis elegans. The neuronal circuit communicates with the gonad via the neurotransmitter serotonin to limit somatic differentiation of tumorous germline cells. Regulated Ire1-dependent decay of transcripts encoding the neuropeptide FLP-6 plays a crucial role in controlling the integrity of the circuit and preventing somatic-fate acquisition by germline tumor cells.

ELIFE (2021)

Add to Collection

Article Oncology

Comparative Pre-clinical Efficacy of Chinese and Indian Cultivars of Bitter Melon (Momordica charantia) against Pancreatic Cancer

Kushal Kandhari, Sandeep Paudel, Komal Raina, Chapla Agarwal, Rama Kant, Michael F. Wempe, Cindy O'Bryant, Rajesh Agarwal

Summary: Comparative pre-clinical studies showed that Chinese and Indian bitter melon varieties exhibit comparable efficacy in inhibiting pancreatic cancer cell proliferation, inducing cell death, suppressing tumor growth, and decreasing angiogenesis. The geographical availability of a particular cultivar should not be a limiting factor in selecting a variant for clinical trials.

JOURNAL OF CANCER PREVENTION (2021)

Add to Collection

Article Cell Biology

Steroid-induced fibroblast growth factors drive an epithelial-mesenchymal inflammatory axis in severe asthma

Riccardo Guidi, Daqi Xu, David F. Choy, Thirumalai R. Ramalingam, Wyne P. Lee, Zora Modrusan, Yuxin Liang, Scot Marsters, Avi Ashkenazi, Alison Huynh, Jessica Mills, Sean Flanagan, Shannon Hambro, Victor Nunez, Laurie Leong, Ashley Cook, Tiffany Hao Tran, Cary D. Austin, Yi Cao, Christine Clarke, Reynold A. Panettieri, Cynthia Koziol-White, William F. Jester, Fen Wang, Mark S. Wilson

Summary: Asthma and inflammatory airway diseases restrict lung airflow and function. Inhaled corticosteroids (ICSs) can reduce inflammation and improve symptoms, but some severe asthma patients do not benefit from ICS. This study identified a corticosteroid-driven fibroblast growth factor (FGF)-dependent inflammatory axis and found that combination therapy with pan-FGF receptor inhibitors and corticosteroids can prevent both eosinophilic and steroid-induced neutrophilic inflammation.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Biology

Endoplasmic reticulum stress activates human IRE1α through reversible assembly of inactive dimers into small oligomers

Vladislav Belyy, Iratxe Zuazo-Gaztelu, Andrew Alamban, Avi Ashkenazi, Peter Walter

Summary: Protein folding homeostasis in the endoplasmic reticulum is regulated by the unfolded protein response (UPR), with Inositol-requiring enzyme 1 (IRE1) playing a key role in signal transmission. This study used a two-color single-molecule tracking approach to investigate the oligomerization of IRE1 in live cells. The results suggest that IRE1 exists as a constitutive homodimer and assembles into small oligomers upon ER stress, with its lumenal domain governing the formation of inactive dimers and stress-dependent oligomers.

ELIFE (2022)

Add to Collection

Meeting Abstract Oncology

A phase Ib study of the combination of alisertib (Aurora A kinase inhibitor) and MLN0128 (dual TORC1/2 Inhibitor) in patients with advanced solid tumors, final expansion cohort data.

S. Lindsey Davis, Alexis Diane Leal, Wells A. Messersmith, Christopher Hanyoung Lieu, Elaine T. Lam, Bradley Corr, Cindy L. O'Bryant, Natalie Julie Serkova, Todd Pitts, Jennifer Robinson Diamond

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Tumor lysis syndrome (TLS) in acute myeloid leukemia (AML) patients treated with azacitidine (AZA) and venetoclax (VEN).

Joanna Q. Huang, Emmeline Academia, Daniel Aaron Pollyea, Jonathan Aaron Gutman, Andrew Hammes, Stephanie Chase, Cindy L. O'Bryant, Jeff Kaiser

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Toxicology

Time-dependent changes in kidney injury biomarkers in patients receiving multiple cycles of cisplatin chemotherapy

Blessy George, Xia Wen, Nickie Mercke, Madeleine Gomez, Cindy O'Bryant, Daniel W. Bowles, Yichun Hu, Susan L. Hogan, Melanie S. Joy, Lauren M. Aleksunes

TOXICOLOGY REPORTS (2020)

Add to Collection

Meeting Abstract Oncology

Pharmacokinetics and safety following a single oral dose of niraparib in patients with moderate hepatic impairment.

Mehmet Akce, Anthony B. El-Khoueiry, Sarina Anne Piha-Paul, Emeline Bacque, Peng Pan, Zhi-Yi Zhang, Reginald Ewesuedo, Divya Gupta, Ashley Milton, Patricia Judson, Cindy L. O'Bryant

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.